XML 19 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 77,106 $ 42,127
General and administrative 34,452 25,704
Acquired in-process research and development   15,199
Total operating expenses 111,558 83,030
Loss from operations (111,558) (83,030)
Other income (expense):    
Interest and investment income 17,360 10,201
Other expense, net (62) (62)
Total other income, net 17,298 10,139
Net loss $ (94,260) $ (72,891)
Net loss per share attributable to common shareholders - basic $ (1.68) $ (2.42)
Net loss per share attributable to common shareholders - diluted $ (1.68) $ (2.42)
Weighted-average common shares outstanding used in net loss per share - basic 56,161,249 30,123,316
Weighted-average common shares outstanding used in net loss per share - diluted 56,161,249 30,123,316